CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Verrica Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Verrica Pharmaceuticals Inc
44 West Gay Street, Suite 400
Phone: (484) 453-3300p:484 453-3300 WEST CHESTER, PA  19380  United States Ticker: VRCAVRCA
Business Summary
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. It is engaged in developing YCANTH (VP-102) for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Paul B.Manning 69 12/1/2017 12/1/2015
President, Chief Executive Officer, Director JaysonRieger 49 11/5/2024 12/1/2015
Interim Chief Financial Officer, Interim Principal Financial Officer John J.Kirby 53 11/5/2024 11/5/2024
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 71 (As of 12/31/2024)
Outstanding Shares: 92,490,993 (As of 5/7/2025)
Shareholders: 15
Stock Exchange: NASD
Federal Tax Id: 463137900
Fax Number: (302) 636-5454


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, June 2, 2025